Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …

Protein post-translational modification (PTM) is a covalent process that occurs in proteins
during or after translation through the addition or removal of one or more functional groups …

Neoadjuvant immune-checkpoint blockade therapy only benefits a limited fraction of patients
with glioblastoma multiforme (GBM). Thus, targeting other immunomodulators on myeloid …

Glioblastoma (GBM) is the most aggressive form of primary brain tumor, for which effective
therapies are urgently needed. Cancer cells are capable of evading clearance by …

Simple Summary All cells are covered in a thick layer of sugar molecules known as glycans.
Changes to this sugar coat are common in cancer, and in particular cancer cells often …

Siglecs are a family of sialic acid–binding receptors expressed by cells of the immune
system and a few other cell types capable of modulating immune cell functions upon …

Cancer immunotherapy in the form of immune checkpoint inhibitors and cellular therapies
has improved the treatment and prognosis of many patients. Nevertheless, most cancers are …

Immune checkpoint blockade (ICB) has substantially improved the prognosis of patients with
cancer, but the majority experiences limited benefit, supporting the need for new therapeutic …

Aberrant glycosylation is a key feature of malignant transformation. Hypersialylation, the
enhanced expression of sialic acid-terminated glycoconjugates on the cell surface, has …

Pancreatic ductal adenocarcinoma (PDA) is one of the deadliest cancers and is projected to
soon be the second leading cause of cancer death. Median survival of PDA patients is 6–10 …